23 Feb MEDTRONIC RECEIVES FDA APPROVAL FOR INTERSTIM X PRIMARY SNM DEVICE
Medtronic announced FDA approval for InterStim X™ which is a primary cell IPG not needing external recharge of the internal implanted battery. InterStim X is indicated for the treatment of OAB, chronic fecal incontinence (FI), and urinary retention. The battery with constant current lasts 10-15 years depending on the energy settings which roughly doubles the previous primary cell device InterStim II. The system requires management of an external programming device which looks like a smart phone that communicates with a separate receiver used to connect to the internal pulse generator. Both patient devices require recharging with standard charging cords but the 11 therapy settings can be changed remotely. The weight and size of Interstim II and Interstim X are the same.